PEB Stock Overview
A cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Pacific Edge Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$0.15 |
| 52 Week High | NZ$0.15 |
| 52 Week Low | NZ$0.071 |
| Beta | 0.96 |
| 11 Month Change | 53.06% |
| 3 Month Change | 54.64% |
| 1 Year Change | 20.97% |
| 33 Year Change | -89.80% |
| 5 Year Change | -28.57% |
| Change since IPO | -14.28% |
Recent News & Updates
Further Upside For Pacific Edge Limited (NZSE:PEB) Shares Could Introduce Price Risks After 33% Bounce
Sep 16
Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation
Aug 16Recent updates
Further Upside For Pacific Edge Limited (NZSE:PEB) Shares Could Introduce Price Risks After 33% Bounce
Sep 16Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation
Aug 16Investors Holding Back On Pacific Edge Limited (NZSE:PEB)
Apr 30Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation
Feb 19Lacklustre Performance Is Driving Pacific Edge Limited's (NZSE:PEB) 30% Price Drop
Dec 18Fewer Investors Than Expected Jumping On Pacific Edge Limited (NZSE:PEB)
Jun 06Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year
May 27We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely
May 23Companies Like Pacific Edge (NZSE:PEB) Are In A Position To Invest In Growth
Sep 06Pacific Edge (NZSE:PEB) Is In A Good Position To Deliver On Growth Plans
May 31Pacific Edge (NZSE:PEB) Is In A Strong Position To Grow Its Business
Jan 17We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely
Jun 05Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?
May 14Don't Ignore The Fact That This Insider Just Sold Some Shares In Pacific Edge Limited (NZSE:PEB)
Mar 21Did The Underlying Business Drive Pacific Edge's (NZSE:PEB) Lovely 750% Share Price Gain?
Mar 13Have Insiders Been Selling Pacific Edge Limited (NZSE:PEB) Shares?
Feb 14
Pacific Edge Limited's (NZSE:PEB) Profit Outlook
Jan 18How Much Of Pacific Edge Limited (NZSE:PEB) Do Insiders Own?
Dec 23Did You Participate In Any Of Pacific Edge's (NZSE:PEB) Incredible 434% Return?
Nov 21Shareholder Returns
| PEB | NZ Biotechs | NZ Market | |
|---|---|---|---|
| 7D | 42.9% | -1.1% | 0.3% |
| 1Y | 21.0% | 13.1% | 6.3% |
Return vs Industry: PEB exceeded the NZ Biotechs industry which returned 13.1% over the past year.
Return vs Market: PEB exceeded the NZ Market which returned 6.3% over the past year.
Price Volatility
| PEB volatility | |
|---|---|
| PEB Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in NZ Market | 10.1% |
| 10% least volatile stocks in NZ Market | 3.1% |
Stable Share Price: PEB's share price has been volatile over the past 3 months.
Volatility Over Time: PEB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of NZ stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 114 | Peter Meintjes | www.pacificedgedx.com |
Pacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer.
Pacific Edge Limited Fundamentals Summary
| PEB fundamental statistics | |
|---|---|
| Market cap | NZ$121.79m |
| Earnings (TTM) | -NZ$29.53m |
| Revenue (TTM) | NZ$25.23m |
4.8x
P/S Ratio-4.1x
P/E RatioIs PEB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEB income statement (TTM) | |
|---|---|
| Revenue | NZ$25.23m |
| Cost of Revenue | NZ$11.75m |
| Gross Profit | NZ$13.48m |
| Other Expenses | NZ$43.01m |
| Earnings | -NZ$29.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.036 |
| Gross Margin | 53.42% |
| Net Profit Margin | -117.07% |
| Debt/Equity Ratio | 0.5% |
How did PEB perform over the long term?
See historical performance and comparison